A repurposed veterinary medication, NUZ-001, helped ALS patients live longer and slowed disease progression in a long-term study.| ALS News Today
Various adaptations and equipment are available that can help a person with ALS eat, dress, use the bathroom, and move around.| ALS News Today
Neither memantine nor trazodone was able to slow amyotrophic lateral sclerosis (ALS) disease progression in a platform clinical trial.| ALS News Today
An analysis in 62 ALS patients who followed the Phase 2b study's rules (protocol) found a 37.4% ALSFRS-R difference with PrimeC vs. placebo.| ALS News Today
ALS speech problems are caused by a weakening of the muscles of the mouth and throat and worsen over time as the disease progresses.| ALS News Today
Exercise has multiple benefits for people with ALS, such as preserving muscle strength and mobility, and increasing overall quality of life.| ALS News Today
PrimeC slowed lung function decline and complication-free survival when treatment started early, per data from a Phase 2b ALS clinical trial.| ALS News Today
Starting treatment with PrimeC six months sooner was associated with slower disease progression and a survival benefit for ALS patients.| ALS News Today
While traveling with friends, columnist Juliet Taylor is reminded of the importance of living out loud, especially in the face of ALS.| ALS News Today
PrimeC led to improvements in iron accumulation in people with amyotrophic lateral sclerosis (ALS) in a clinical trial, new data showed.| ALS News Today
Clene submitted new data on CNM-Au8 to the FDA ahead of an upcoming meeting to discuss potential accelerated approval for the ALS therapy.| ALS News Today